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The discovery that their neonatal diabetes is caused by gain-of-function mutations in the KATP channel has
enabled many patients to switch from insulin to oral sulphonylurea drugs. Here, I review molecular, physio-
logical, and clinical features of this change in therapy.Neonatal diabetes (ND) is a relatively rare
genetic disorder that affects about 1 in
200,000 live births (Hattersley and Ash-
croft, 2005). It is characterized by dia-
betes that presents within the first 6
months of life, which may either be per-
manent or follow a remitting-relapsing
time course. While there are multiple
causes of ND, activating mutations in the
ATP-sensitive potassium (KATP) channel
subunits Kir6.2 (KCNJ11) and SUR1
(ABCC8) are the most common, account-
ing for around 50% of cases. Rarely,
patients with these mutations may have
diabetes diagnosed outside the neonatal
period.
About a third of ND patients with Kir6.2
mutations also have neurological symp-
toms (Hattersley and Ashcroft, 2005). A
minority have DEND syndrome, which is
characterized by muscle weakness, se-
vere mental and motor developmental
delay, epilepsy, and neonatal diabetes.
Most, however, have an intermediate
condition (iDEND syndrome), which mani-
fests as ND accompanied by delayed
speech and walking and often muscle
weakness.
The KATP Channel: A Metabolic
Sensor
The KATP channel is a plasma membrane
K-selective pore that links cellular metab-
olism and electrical excitability in nu-
merous cell types (Nichols, 2006). At low
levels of metabolism, channel activity
keeps the membrane potential at a nega-
tive (hyperpolarized) level, damping down
electrical activity. Conversely, closure of
KATP channels bymetabolically generated
ATP precipitates membrane depolariza-
tion, stimulating action potential firing
and its attendant cellular consequences.In this way, the KATP channel transduces
alterations in metabolism into changes in
cellular processes such as hormone
secretion, muscle contraction, and neuro-
transmitter release.
Pancreatic b cells, for example, match
insulin release to fluctuations in blood glu-
cose via metabolically induced changes
in KATP channel activity, secretion being
stimulated by KATP channel closure. Sul-
phonylurea drugs, which bind directly to
the KATP channel and cause it to shut,
also stimulate insulin secretion (Gribble
and Reimann, 2003).
KATP channels comprise four pore-
forming Kir6.2 subunits and four regula-
tory sulphonylurea receptor subunits:
either SUR1 (endocrine cells, many neu-
rones), SUR2A (heart and skeletal mus-
cle), or SUR2B (smooth muscle, some
neurones) (Nichols, 2006). The exquisite
sensitivity of the KATP channel to small
changes in metabolism derives from its
dual regulation by adenine nucleotides.
It is closed by nonhydrolytic binding of
ATP to Kir6.2 and opened by interaction
of Mg-nucleotides with SUR. Channel
activity is thus determined by the balance
between these inhibitory and stimulatory
effects.
ND Mutations Impair Insulin
Secretion
All mutations that cause ND increase the
whole-cell KATP current in heterologous
expression studies (Ashcroft, 2007). This
reduces glucose-dependent depolariza-
tion of the b cell and prevents activation
of electrical activity and insulin secretion.
In general, the larger the KATP current,
the more severe the disease phenotype.
Although a few ND mutations increase
the whole-cell KATP current by enhancingCell Metabolismthe density of KATP channels in the plas-
malemma (Mankouri et al., 2006), most
act by decreasing the ability of MgATP
to inhibit the channel (Gloyn et al., 2004;
reviewed by Ashcroft, 2007).
To date, >40 mutations in Kir6.2, at 26
distinct residues, have been linked to
ND, the most prevalent being R201H
(which just produces diabetes) and
V59M (which causes iDEND). One cluster
of mutations lines the putative ATP-
binding pocket and is suggested to act
by preventing ATP binding. Many muta-
tions, however, lie distant to the ATP-
binding site in regions of the channel
known to be involved in opening and
closing (gating) of the pore. These muta-
tions decrease ATP inhibition allosteri-
cally, by stabilizing the open conformation
of the channel in both the absence and
presence of ATP. A few Kir6.2 mutations
also appear to enhance the stimulatory
effect of Mg-nucleotides at SUR1. Impor-
tantly, it is the magnitude of the change in
KATP current and not the underlying
molecular mechanism that dictates the
clinical phenotype.
SUR1 mutations linked to ND may also
act directly, by enhancing MgATP activa-
tion, or indirectly, by altering channel
gating and reducing ATP inhibition at
Kir6.2 (reviewed by Ashcroft, 2007). Inter-
estingly, ND-SUR1 mutations generally
decrease ATP sensitivity less than ND-
Kir6.2 mutations. They also cause less
severe disease, with only one patient
with DEND syndrome being reported to
date (Proks et al., 2006).
Extrapancreatic Effects
of ND Mutations
Precisely how ND mutations cause the
neurological features associated with11, March 3, 2010 ª2010 Elsevier Inc. 179
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of speculation. However, KATP channels
are expressed in skeletal muscle and
throughout the brain. A gain-of-function
mutation in a K-channel is expected to
reduce cellular electrical activity: thus,
the simplest explanation for the epilepsy
found in DEND syndrome is that it results
from reduced activity of inhibitory inter-
neurones and a consequent loss of inhib-
itory tone. It is significant that, at least in
the hippocampus, inhibitory neurones
are reported to have a greater density of
KATP channels than excitatory neurones
(Zawar et al., 1999).
The muscle weakness commonly seen
in iDEND patients might reflect the
enhanced activity of either neuronal or
muscle KATP channels. However, the evi-
dence favors a neuronal origin, because
muscle weakness has been observed in
at least one patient with an SUR1 muta-
tion (Proks et al., 2006), despite the lack
of SUR1 expression in muscle. Further-
more, the muscle weakness and ataxic
gait of a patient with a Kir6.2 mutation
was improved by treatment with glicla-
zide, which interacts only with SUR1
(Koster et al., 2008).
A key question is why neurological
symptoms are found only for mutations
that produce very large KATP currents in
functional studies. One possibility is that
this reflects differences in cell metabolism
and/or the complement of ion channels
that regulate the membrane potential in
different tissues. Another conundrum is
that despite the fact that Kir6.2 is ex-
pressed in the heart, no cardiac abnormal-
ities have been reported in patients. This is
also true of mice carrying gain-of-function
mutations targeted to cardiac myocytes
(Koster et al., 2001). Why this is the case
remains unresolved but may be related to
the fact that cardiacKATP channels contain
SUR2A rather than SUR1 subunits.
Mouse Models of ND
Mouse models have traditionally illumi-
nated understanding of human disease,
and ND is no exception. Several mouse
models have been generated that express
KATP channels with reduced ATP sensi-
tivity only in pancreatic b cells (Koster
et al., 2000; Remedi et al., 2009; Girard
et al., 2009). These mice show elevated
blood glucose levels shortly after birth
(or induction of the mutant gene) and
develop severe diabetes within a few180 Cell Metabolism 11, March 3, 2010 ª201weeks. Insulin secretion is markedly
reduced, not only because of a failure of
glucose-dependent KATP closure, but
also due to a progressive decrease in
b cell mass and insulin content and a
loss of normal islet architecture. Normali-
zation of blood glucose levels with either
glibenclamide or insulin (by islet trans-
plantation) therapy prevents the changes
in insulin content and b cell mass, sug-
gesting that they are a secondary conse-
quence of untreated hyperglycemia. Cru-
cially, although glibenclamide was able to
prevent diabetes if given prior to induction
of the mutant Kir6.2 gene, it was unable
to reverse established hyperglycemia
(Remedi et al., 2009). Thus, it appears that
if hyperglycemia is prolonged, it may be
difficult to restore b cell mass, a finding
that has implications for other types of
diabetes as well as ND.
These studies indicate that in mice, the
reduced insulin secretion found in uncom-
pensated ND is not only a consequence of
overactive KATP channels, but also due
to a reduction in insulin content and
b cell mass. To what extent this occurs
in humans is unknown because patients
will have been on insulin (or sulphony-
lurea) therapy since diagnosis.
Therapeutic Implications
The discovery of a KATP channel mutation
is of considerable clinical importance. In
the past, patients with ND were treated
with insulin injections because their clin-
ical characteristics suggested an unusu-
ally early-onset form of type 1 diabetes.
However, the discovery that many
patients had gain-of-function mutations
in KATP channel genes led to an immediate
change in treatment: the use of sulphony-
lurea drugs to block the open channels
(Pearson et al., 2006). Most ND patients
are now managed on sulphonylureas,
which have become the therapy of
choice. This has not only transformed
their quality of life, it has also had marked
clinical benefits. Fluctuations in blood
glucose, a common problem in neonatal
patients, are substantially reduced (Zung
et al., 2004), and hypoglycemic episodes
are far less common. Plasma glucose
levels are also lower, as indicated by a
significant reduction in HbA1C levels
(Pearson et al., 2006), which decreases
the risk of diabetic complications.
Interestingly, oral glucose is far more
effective than intravenous glucose at trig-0 Elsevier Inc.gering insulin secretion in ND patients
treated with sulphonylureas (Pearson
et al., 2006). One hypothesis is that this
difference is due to hormones (incretins),
such as GLP-1 and GIP, that are secreted
in response to the presence of food in the
gut lumen or neurotransmitters, such as
acetylcholine, released in response to
the sight and smell of food. These agents
produce a marked amplification of insulin
secretion primarily by acting on down-
stream targets such as exocytosis. Be-
cause one pathway by which these
agents act requires a KATP-dependent
increase in [Ca2+]i, it is suggested that
stimulatory hormones and neurotransmit-
ters are ineffective in untreated ND, but
that closure of KATP channels by sulpho-
nylureas, which leads to elevation of
[Ca2+]i, renders them operational. The
amplifying effects of glucose itself on
insulin secretion will also be enabled
only after sulphonylureas have closed
mutant KATP channels. The various ampli-
fying pathways are of considerable clin-
ical significance, since they ensure that
insulin secretion in ND patients treated
with drugs is regulated by meals.
Although sulphonylureas are highly
effective in treating most patients, not all
respond. However, there is an excellent
correlation between the patient response
and the extent to which the sulphonylurea
tolbutamide blocks the whole-cell current
through the equivalent heterozygous re-
combinant KATP channel (Pearson et al.,
2006; see also review, Ashcroft, 2007).
When the block is <65%, all patients fail
to respond to sulphonylureas, whereas
when the block is >75%, at least some
patients respond. Thus, mutation-specific
sulphonylurea failure is caused by a re-
duction in drug sensitivity.
Most patients who have successfully
transferred to sulphonylureas were chil-
dren at the time of transfer. Why fewer
adults are able to switch remains unclear,
but studies of mouse models of ND
suggest a possible explanation. Mice
with severe untreated diabetes for more
than 2months have few functioning b cells
(Remedi et al., 2009). No b cell loss
occurs, however, if mice are given insulin
therapy (Remedi et al., 2009). This may
explain why most patients respond to sul-
phonylureas: insulin treatment will have
largely prevented severe hyperglycemia
(and maintained insulin content and
b cell mass). Perhaps those patients with
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failed to respond to drug therapy had
poor long-term blood glucose control,
leading to a decline in b cell mass and
function. It is an acknowledged fact that
insulin therapy does not regulate glucose
homeostasis perfectly, and thus older
patients, who have taken insulin for
longer, would be less likely to be able to
transfer to sulphonylureas.
In type 2 diabetes, sulphonylurea effi-
cacy often declines with time, and most
patients eventually progress to insulin. It
is too early to say whether this will be
the case for ND, as widespread sulphony-
lurea therapy has only been implemented
in this patient groupwithin the last 4 years.
However, a few patients have been
successfully treated for many years with
these drugs without secondary failure.
Sulphonylurea Therapy
and Neurological Complications
The neurological complications associ-
ated with DEND and iDEND are believed
to arise from hyperactivity of KATP chan-
nels in nerve and muscle. An important
question, therefore, is whether sulphony-
lureas can ameliorate the neurological
problems. There is increasing evidence
that this is the case. Several patients with
iDEND have reported improved motor
tone, coordination, and gait after switch-
ing to sulphonylurea therapy (Slingerland
et al., 2006; Mlynarski et al., 2007; Shimo-
mura et al., 2007; Koster et al., 2008).
Enhanced cognitive function (Mlynarski
et al., 2007; Slingerland et al., 2008) and
abolition of epileptic seizures (Shimomura
et al., 2007) have also been described.
These results suggest that sulphonylur-
eas cross the blood-brain barrier in suffi-
cient amounts to close neuronal KATP
channels.Consistentwith this idea, a clear
increase in blood flow in some brain
regions was seen following glibenclamide
treatment in SPECT scans (Mlynarski
et al., 2007). This suggests the drug
closes neuronal KATP channels, stimu-
lating neuronal activity and thereby blood
flow.Although these limited examples
suggest that sulphonylureas can indeed
improve mental and motor function, devel-
opment did not return fully to normal. This
may be because of an inability to raise sul-
phonylureas in the brain to a concentration
high enough to close all KATP channels or
because of irreversible neuronal damage
caused by KATP channel overactivity.
More studies are required, in particular to
determine whether early implementation
of drug therapy or higher doses produces
a greater amelioration of neurological
problems.
A consistent finding is that the
sulphonylurea dose required to maintain
normoglycemia declines with time after
transfer. Why this happens is unclear,
but a particular concern is whether
improvements in neurological function
can be maintained when the drug dose
is lowered.Perspectives
The discovery that mutations in Kir6.2 and
SUR1 can cause ND has led to an
increased understanding of the relation-
ship between KATP channel structure and
function and transformed therapy for
patients with these mutations. Neverthe-
less, many questions remain to be an-
swered, of which the most pressing in-
clude why some mutations result in a
remitting-relapsing form of diabetes and
why other mutations cause neurological
problems in addition to diabetes. Com-
parison of the human and mice data sug-
gests that the mouse can provide a
reasonable model for human ND. Analysis
of mouse models of the relevant human
mutations may thus facilitate under-
standing of the questions that remain.REFERENCES
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